Immune Hemolytic Anemia—Selected Topics

Because of the association of AIHA with chronic lymphocytic leukemia, many people with AIHA can be expected to have been treated with purine nucleoside analogues such as fludarabine and cladribine. In 1995, Myint et al reported on 52 patients with AIHA treated with fludarabine, in whom severe AIHA occurred in 12 (23%) after a median of four courses. Nine of these 12 had no prior evidence of AIHA. Eight were retreated with fludarabine at a later time, and severe AIHA recurred in 6.¹ The authors opined that a disturbance of immunoregulatory T cells was responsible for the problem, in that T-cell lymphopenia is a recognized effect of fludarabine. Weiss et al reviewed this subject, and reported on 24 patients with AIHA following fludarabine therapy for chronic lymphocytic leukemia.² Most of the patients developed the AIHA after one to three courses of drug, and seven (29%) died of complications related to the AIHA. Of 8 patients rechallenged with fludarabine at a later time, 7 had recurrent AIHA, and 3 died. The authors propose as a mechanism the release of a suppressed autoanti-body to a native erythrocyte antigen.

This problem has also been reported after the use of cladribine. Fleischman and Croy reported a patient with severe AIHA that developed a few weeks after treatment of chronic lymphocytic leukemia with cladribine.³ More recently, Aslan et al reported a case of a patient with Walden-ström’s macroglobulinemia who developed warm antibody AIHA a few months after therapy with cladribine.⁴ The authors bolster the causative assumption by noting that cold-mediated IgM antibody is more likely to occur in macro-globulinemia rather than a warm antibody. Byrd et al noted a case of fludarabine-associated AIHA that recurred fatally upon treatment with pentostatin.⁵ 

Clinicians need to be aware of the risk that use of purine nucleoside analogues in treating malignant lymphoproliferative disorders may induce AIHA, and that this may be severe or even fatal at times. There may be a role for rituximab in the treatment of such episodes.⁶ 

While alloantibody formation is a recognized and reasonably common complication of blood transfusion, the possibility of autoantibody formation has not been well recognized. Young et al analyzed over 2600 patients with a positive direct antiglobulin test or indirect antiglobulin test, and identified 41 patients who had both an autoanti-body and an alloantibody. About a third of them developed their autoantibody in close temporal association with alloimmunization following recent transfusion.⁷ Therefore, AIHA developed either concurrently or shortly after alloimmunization from blood transfusion. The authors conclude that AIHA is a potential complication of allogeneic red blood cell transfusions, and recommended supportive treatment with iron and erythropoietin analogues, avoiding further transfusion whenever possible. This complication of red blood cell transfusion may be more common than previously appreciated.⁸ It has also been noted in patients with hemoglobinopathies who have received multiple transfusions.^9,–11 

Immune hemolysis may be a complication of hematopoietic stem cell transplantation when there is a minor ABO blood group incompatibility between the donor and recipient. It occurs most often when the donor is group O and the patient group A, and may occur in up to 10–15% of patients.^12,13 The resultant hemolysis begins within the first 2 weeks after infusion, and may be abrupt in onset and severe, sometimes with accompanying intravascular hemolysis and renal failure.¹⁴ 

The problem has been attributed to the “passenger lymphocyte syndrome,” caused by production of antibody by rapidly proliferating passively-transferred lymphocytes transfused with the stem cell product. Passive transfer of antibody in plasma accompanying the product does not appear to be important, as the hemolysis does not occur immediately. The antibody production and subsequent hemolysis occur while the patient is still pancytopenic from the conditioning regimen, before immune reconstitution occurs. It is thought to be related to the fact that IgG-type anti-A and anti-B are more common in group O persons than in group A and B persons. Hemolysis may also be a result of anti-D, anti-E, anti-s, anti-Jkb and anti-Jka. The hemolysis lasts 5–10 days and gradually subsides as the recipient’s residual incompatible red cells are lysed and replaced by transfused group O cells, or by red cells of donor type produced by engrafting stem cells. Further, antibody production by passenger lymphocytes that do not engraft dissipates.

Several factors appear to predispose to passenger lymphocyte syndrome: use of cyclosporine alone without methotrexate for graft-vs-host disease prophylaxis; use of peripheral blood stem cell product rather than bone marrow; use of reduced-intensity preparative regimens; use of a non-genotypically HLA-matched donor; and possibly, use of a female donor. The problem has not been noted with umbilical cord blood stem cell transplantation.

Patients develop rapid onset of hemolysis, associated with a positive direct antiglobulin test and the presence of anti-A or anti-B antibodies in their serum. Evidence of in-travascular hemolysis with accompanying hemoglobinuria and renal failure may ensue.

Management strategies include reduction of the plasma volume of stem cell product, to reduce the amount of anti-A and anti-B infused. While passive transfer of antibody is not thought to be the main problem, large volumes of anti-A or anti-B in donor plasma can sometimes cause hemolysis, as well.¹⁵ Red cell transfusions should be with compatible cells or group O cells (if patient is type AB, and donor is type A or B, donor cells may be used). Corticosteroids are commonly used. Platelet transfusions and other plasma-containing products should be of recipient type, to minimize infusing anti-A and anti-B, and renal function should be assured. If significant hemolysis occurs, exchange transfusion may be required to replace the patient’s antigen-positive red blood cells with group O red blood cells. Prophylactic red blood cell exchange transfusion has been proposed in some cases.^13,16 

When there is a major ABO-incompatibility, such as when the donor is type A or type B, and the recipent type O, hemolysis may be prevented by removing red cells from the donor product. Persistence of recipient ABO antibodies may lead to persistent hemolysis for a few months, and patients may need to be supported with transfusion of type O blood. Recommendations for blood product support in minor and major ABO-mismatched hematopoietic stem cell transplantation have been reviewed in detail recently by Petz.¹⁴ 

In some reported instances of hemolytic anemia post-hematopoietic stem cell transplantation, the degree of hemolysis exceeded the total erythrocyte volume of the recipient, suggesting that transfused group O cells, in addition to the recipient’s native cells, were also being lysed—a phenomenon called “bystander” hemolysis. This hemolysis of cells that are negative for the antigen against which the antibody is directed is poorly understood and controversial.^13,16,17 

Autoimmune hemolytic anemia has also been reported following hematopoietic stem cell transplantation. This is thought to be due to antibody being produced by the donor immune system against antigens on red cells of donor origin, hence AIHA. In a number of cases studied, no evidence of residual recipient cells was found, leading to the conclusion that the cause was an autoimmune reaction of the graft against its own product. A report in a pediatric population noted an incidence of 6%, with a median time of onset of 4 months after transplant; mortality was quite high, perhaps worsened by the additional immunosuppressive therapy required to manage the AIHA.¹⁸ It was more common when transplant was performed for metabolic diseases than for malignant disorders. It was also reported to occur in 5% of 6-month survivors of T cell–depleted transplants¹⁹ in one report, and in 9 of a group of 293 (3%) transplanted patients.²⁰ In the latter study, 5 patients had warm antibody AIHA, and 4 had cold agglutinin disease. Patients with warm AIHA developed it later, between 6 and 18 months, versus 2–8 months for those with cold agglutinins. Additional reports have included several cases following cord blood transplants, with resultant AIHA and Evans syndrome.^21,–25 There have been reports of successful therapy of AIHA following hematopoietic stem cell transplantation with rituximab.^26,27 

Immune hemolysis has also been associated with solid organ transplantation.^28,–30 This is thought also to relate to passenger lymphocyte syndrome and involves mainly group O donors, though a few have been in AB recipients with non-AB donors. The risk and degree of hemolysis is in proportion to the mass of lymphocytes transplanted—lowest in kidney (antibody in 17%, hemolysis in 9%), next higher in liver (antibody in 40%, hemolysis in 29%), and highest in heart-lung transplants (antibody in 70%, hemolysis in 70%). The hemolysis is of rapid onset, with a positive direct antiglobulin test and detectable serum antibody. The antibody is usually directed against an Rh antigen, primarily anti-D. Onset is between 3 and 24 days. In one study of 43 patients, 36 had IgG antibody, 35 had C3, and 28 had both.²⁸ The average transfusion requirement was 6.5 units. In contrast to hematopoietic cell transplants, where the patient’s red blood cells eventually become replaced by donor marrow–produced ones, patients with solid organ transplants continue to make red cells that are incompatible with the transplanted organ. However, hemolysis is generally transient, since the lymphocytes transferred with the donor organ do not proliferate indefinitely and do not engraft.

Management of hemolysis in solid organ transplant patients includes transfusion of group O red cells, avoidance of ABO-incompatible plasma products, and maintenance of adequate renal function. Sometimes red blood cell exchange is necessary to decrease the volume of incompatible cells that can be targets for hemolysis. Transfused red cells should be ABO-identical or compatible with recipient serum, irrespective of donor organ type. If the donor and recipient have different blood type, products should be used that are ABO-compatible with both the recipient and donor red cells, as well as the donor organ tissue type, to avoid transfusing antibody that may contribute to hemolysis. Guidelines for blood product selection in patient with ABO-mismatched solid organ transplants are offered by Petz.¹⁴ 

In an early review of AIHA, the most common cause of death was pulmonary embolism (4 of 47 patients).³¹ All of these patients had had a splenectomy, and all were receiving corticosteroid therapy. In a more recent review by Pullarkat et al, 8 of 30 patients (27%) suffered from an episode of venous thromboembolism.³² A total of 9 had a detectable lupus anticoagulant and 17 had anticardiolipin antibodies detected. Among the 8 with thrombosis, 5 had a lupus anticoagulant and 4 had anticardiolipin antibodies. The authors attributed the thrombosis to disruption and loss of red cell membranes, resulting in exposure of phos-phatidyl serine, and a subsequent surface for formation of tenase and prothrombinase complexes. Other factors implicated in the thrombotic tendency in patients with AIHA included cytokine-induced expression of monocyte or endothelial tissue factors. The authors postulated that the detection of a lupus anticoagulant identifies patients with AIHA at particularly high risk for venous thromboembolism and suggested that serious consideration be given to prophylactic anticoagulation in such patients. However, they point out that thrombosis also occurred in 15% of AIHA patients who did not have a lupus anticoagulant, so other factors are likely at work.

Kokori et al, in a review of AIHA in patients with systemic lupus erythematosus, found the risk of thrombosis to be increased more than 4-fold, particularly in the presence of IgG anticardiolipin antibody.³³ The association of serologic indications of lupus, namely a false-positive test for syphilis, has been noted in the past in patients with AIHA by Conley and Savarese.³⁴ 

Hendrick has reviewed this issue recently and concluded that patients with AIHA are indeed at high risk for thromboembolism. In an audit of 23 patients with warm antibody AIHA and 5 with cold agglutinin hemolysis, venous thromboembolism was noted in 6, of which 4 cases were fatal. These patients did not have detectable anti-phospholipid antibodies. In an analysis of 36 hemolytic episodes, venous thromboembolism occurred in 5 of 15 without anticoagulant prophylaxis, but in only 1 of 21 in which prophylaxis was used.³⁵ 

Although it is premature to recommend anticoagulant prophylaxis in general for patients with hemolytic episodes from AIHA, consideration might be given to those at particularly high risk, such as those with evidence of coexisting antiphospholipid antibodies.

Patients with lymphoproliferative disorders are well known to have a higher risk for development of AIHA; this is particularly true of chronic lymphocytic leukemia. Interestingly, there may also be an increased risk for future development of lymphoproliferative disorders in patients with AIHA. Sallah et al reported on 107 patients with AIHA, of whom 67 had idiopathic AIHA, and 40 had an associated immune disorder (e.g., rheumatoid arthritis, temporal arteritis, Crohn’s disease, lupus, thyroiditis, Sjögren’s syndrome). Nineteen of the 107 (18%) subsequently developed a malignant lymphoproliferative disorder, at a median of 26 months after onset of the AIHA.³⁶ Risk factors for development of such a disorder were age, the presence of an underlying autoimmune disease, and a coexistent serum gammopathy. None of the patients had underlying HIV infection. The authors postulate that the development of a malignant lymphoid disorder is likely a multistep process, with an earlier proliferative phase involving chronic antigenic stimulation prior to a mutation leading to malignant change.

The standard therapeutic approaches to treatment of AIHA include corticosteroids, splenectomy and immunosuppressive drugs. In the past several years, certain newer therapies have become available, and have shown evidence of success. These are primarily used in patients who are not candidates for or fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids.

Flores et al reviewed the cases of 73 patients treated with IVIG, and found responses in 29 (40%).³⁷ Children were more likely to respond, as were patients with initial hepatomegaly and lower initial hemoglobin levels.

Danazol, which has been used more in refractory cases of immune thrombocytopenia, has also been used in AIHA. Ahn reported good to excellent results in the majority of patients treated.³⁸ In another series of 17 patients treated with the combination of prednisone and danazol, excellent responses were noted in 80% who received the combination as first-line therapy; treatment was less effective in patients who had relapsed and in those with Evans’ syndrome.³⁹ 

Howard et al reported on the use of mycophenolate mofetil in 4 patients with refractory AIHA.⁴⁰ Patients were treated with 500 mg per day initially, then 1000 mg per day. All 4 had a complete or good response.

There has been considerable interest in the past several years in the use of the monoclonal antibodies widely used in the treatment of B-cell lymphoid neoplasms, namely rituximab (Rituxan^®), and to a lesser extent alemtuzumab (Campath-1H^®). Zecca et al first reported on a child with pure red cell aplasia and AIHA treated successfully with rituximab and IVIG.⁴¹ Another report, in 5 children with AIHA, described excellent responses, but with a resultant not-unexpected prolonged B-cell deficiency.⁴² Shanafelt et al reported on 5 patients, of whom 2 had a complete response. In an additional 4 patients with Evans’ syndrome, complete responses occurred in either the immune thrombocytopenia or the AIHA, but not both.⁴³ Trape et al noted the benefits of rituximab for residual AIHA in 5 patients following chemotherapy of a lymphoproliferative disorder.⁴⁴ Mantadakis et al offered a case report of a patient with refractory Evans’ syndrome who responded for 7 months to rituximab, and then responded a second time after relapse.⁴⁵ Ramanathan et al noted 2 patients with refractory disease who demonstrated prolonged remissions with rituximab.⁴⁶ Not all reports have been favorable, however: Zaja et al noted no response to rituximab in 2 patients with AIHA, though a patient with cold agglutinin disease responded well.⁴⁷ 

Gupta et al reported on the combined use of rituximab, cyclophosphamide and dexamethasone in 8 patients with refractory AIHA in the setting of chronic lymphocytic leukemia. The results were excellent, including in relapsed patients, with 5 patients converting to negative DAT status.⁴⁸ 

There has been only limited experience with alemtuzumab in AIHA, with one report noting responses in 3 of 4 patients treated.⁴⁹ 

The role of monoclonal antibodies in the therapy of autoimmune cytopenias has been reviewed in detail recently.⁵⁰ It is reasonable to conclude that monoclonal antibody therapy, specifically rituximab, is a safe and effective therapy for AIHA. It is likely that as our experience with the drug evolves, it will be used at an earlier point in therapy, before more toxic immunosuppressives, rather than only in refractory cases.